Application 125557

Type
BLA
Sponsor
AMGEN

Related Records

Application Products

ProductDrugIngredientFormStrengthReference drugReference standard
001BLINCYTOBLINATUMOMABINJECTABLE;INJECTION35MCGNoNo

NDC Listings For This Application

NDCNameNonproprietary nameLabelerMarketing categoryStatus
55513-160BLINCYTOblinatumomabAmgen IncBLACurrent
55513-160BLINCYTOblinatumomabAmgen IncBLACurrent
55513-160BLINCYTOblinatumomabAmgen IncBLACurrent
55513-160BLINCYTOblinatumomabAmgen IncBLACurrent
55513-160BLINCYTOblinatumomabAmgen IncBLACurrent
55513-160BLINCYTOblinatumomabAmgen IncBLACurrent
55513-160BLINCYTOblinatumomabAmgen IncBLACurrent
55513-160BLINCYTOblinatumomabAmgen IncBLACurrent

Documents

DocumentSubmission typeDate
83879SUPPL 2025-10-23
83867SUPPL 2025-10-22
82136SUPPL 2025-05-05
82074SUPPL 2025-04-30
82073SUPPL 2025-04-30
80615SUPPL 2024-12-18
80610SUPPL 2024-12-18
78812SUPPL 2024-06-18
78804SUPPL 2024-06-14
77444SUPPL 2024-02-09
77432SUPPL 2024-02-09
74571SUPPL 2023-06-21
74570SUPPL 2023-06-21
74561SUPPL 2023-06-21
74560SUPPL 2023-06-21
72796SUPPL2022-12-06
70211SUPPL2022-02-22
70196SUPPL2022-02-22
70195SUPPL2022-02-22
66759SUPPL2021-03-12
66754SUPPL2021-03-12
62294SUPPL2020-03-24
62265SUPPL2020-03-23
62221SUPPL2020-03-23
59049SUPPL2019-06-13
58378SUPPL2019-04-24
58377SUPPL2019-04-24
58354SUPPL2019-04-19
58353SUPPL2019-04-19
53757SUPPL2018-04-20
53582SUPPL2018-04-01
53544SUPPL2018-03-29
50570SUPPL2017-12-01
50549SUPPL2017-12-01
50548SUPPL2017-12-01
48987SUPPL2017-07-14
48952SUPPL2017-07-12
48820SUPPL2017-06-26
48289SUPPL2017-05-09
48244SUPPL2017-05-05
45208SUPPL2016-08-30
45207SUPPL2016-08-30
45185SUPPL2016-08-30
45184SUPPL2016-08-30
43339ORIG2015-01-12
24093ORIG2014-12-05
9787ORIG2014-12-04
39995ORIG2014-12-03
63253ORIG1900-01-01
63252ORIG1900-01-01
63251ORIG1900-01-01